Relapse · patients with acute asthma
Intramuscular corticosteroids showed no clear difference in relapse compared with oral corticosteroids (low certainty).
3 findings from 1 review
RR 0.94 [0.72, 1.24]
9 studies · 804 participants
Low
RR 0.74 [0.51, 1.07]
7 studies · 742 participants
Moderate
RR 0.99 [0.74, 1.33]
5 studies · 556 participants
Low
Adverse events · patients with acute asthma
Intramuscular corticosteroids showed no clear difference in adverse events compared with oral corticosteroids (low certainty).
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · patients with acute asthma
1 finding from 1 review
Persistence of symptoms · patients with acute asthma
Intramuscular corticosteroids showed no clear difference in symptom persistence compared with oral corticosteroids (low certainty).
1 finding from 1 review
24‐hour beta agonist use · patients with acute asthma
Intramuscular corticosteroids showed no clear difference in 24‐hour beta agonist use compared with oral corticosteroids (low certainty).
1 finding from 1 review
AHI · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Desaturation index (number of times per hour of sleep time that the blood's O₂ level drops by a certain proportion from baseline) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Respiratory arousal index (number of times per hour of sleep time that an increased respiratory effort without a decrease in oxygen saturation is recorded) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lung function: FEV1 mL (change from baseline) · people with bronchiectasis
1 finding from 1 review
Number of participants improved · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in number of participants improved compared with placebo (low certainty).
1 finding from 1 review
Lung function (spirometry indices) ‐ FVC (in L, end study minus baseline values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ diffusion capacity % predicted (end of study) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ RV % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ TLC % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Exacerbations · people with bronchiectasis
1 finding from 1 review
Pseudomonas aeruginosa (P aeruginosa) colonisation · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in pseudomonas aeruginosa (P aeruginosa) colonisation compared with placebo (low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · people with bronchiectasis
1 finding from 1 review
FVC (% predicted) Change from baseline · people with bronchiectasis
1 finding from 1 review